Avelas Biosciences to Present at 2018 Cantor Global Healthcare Conference

Wednesday, September 26, 2018 General News
Email Print This Page Comment bookmark
Font : A-A+

SAN DIEGO, Sept. 26, 2018 /PRNewswire/ -- Avelas Biosciences, Inc., a clinical stage oncology-focused platform technology

company that is developing products to advance a new standard-of-care for cancer surgery and therapeutic intervention, today announced that Ms. Kyri Van Hoose, Head of Finance, will present at the 2018 Cantor Global Healthcare
Conference on Wednesday, October 3, 2018, at 8:35 a.m. EDT (5:35 a.m. PDT) in New York City.

About Avelas Biosciences

Avelas Biosciences is a San Diego-based biotechnology company focused on developing products to advance a new standard-of-care for cancer surgery and therapeutic intervention. The company's lead candidate, AVB-620, has completed a Phase 1b clinical trial assessing safety, pharmacokinetics and fluorescence properties using tissue image analysis. A Phase 2 clinical trial for AVB-620 in breast cancer is ongoing. In addition, the company is advancing a therapeutic program, which utilizes the same technology platform. Avelas was founded on technology from Roger Y. Tsien, Ph.D., co-winner of the 2008 Nobel Prize in chemistry. For additional information, please visit www.avelasbio.com.

 

Cision View original content:http://www.prnewswire.com/news-releases/avelas-biosciences-to-present-at-2018-cantor-global-healthcare-conference-300719108.html

SOURCE Avelas Biosciences, Inc.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store